Semax dosage: the intranasal doses studied — and why none are FDA-approved

There is an unavoidable honesty problem at the center of any Semax dosing discussion. The compound is a genuine, decades-old Russian prescription medicine, so unlike most research peptides it actually has regimens that were used on real patients. But none of those regimens were set by a Western regulator, the studies behind them are small and single-country, and the version most people buy online is a chemically modified one that was never the drug those studies tested. For what Semax does and how well-supported it is, start with the Semax evidence monograph; this page is only about the numbers people use, and how much weight they can bear.

The route is fixed: intranasal

Semax is delivered through the nose, as drops instilled into each nostril, rather than injected or swallowed.^[1] The route is not incidental. A pharmacokinetic study in rats found that after intranasal administration the intact peptide reaches the brain and bloodstream, the basis for the nose-to-brain delivery the drug relies on — though the same line of work shows Semax is rapidly broken down by peptidases, which is part of why it is dosed repeatedly through the day rather than once.^[2] Any “dose” for Semax therefore means a quantity of solution dripped intranasally, typically split between nostrils and across several administrations.

What Russian clinical practice actually used

The most defensible doses are the ones tied to published clinical work, almost all of it in acute ischemic stroke. In trials run by the originating Russian groups, Semax was given as a daily intranasal course over a span of days during the acute stroke window, as an add-on to standard care.^[3]A later study comparing patients at different stages of ischemic stroke likewise used a fixed daily intranasal regimen rather than an as-needed dose.^[4] Two features matter for anyone reading across to their own use. First, these were therapeutic stroke doses — higher daily totals than the casual nootropic use the peptide is marketed for online. Second, they were given under clinical supervision for a defined, short course, not taken open-endedly. The registered Russian product carries its own labeled concentrations and instructions; that label, not a forum consensus, is the actual source of any sanctioned figure, and it exists only within the Russian regulatory system.^[5]

The modified form most people actually buy

Here the gap between the studied drug and the sold product widens. The Semax used in the Russian clinical literature is the plain heptapeptide. Much of what is sold to consumers in the West is N-acetyl semax amidate — a version with an acetyl group added at one end and an amide at the other, modifications marketed as making it more resistant to the peptidases that clear the parent compound and therefore longer-acting.^[2] The chemistry rationale is plausible on its face, because the parent peptide’s rapid enzymatic breakdown is well documented.^[2] But the practical consequence is rarely stated plainly: the modified molecule is not the molecule the stroke trials administered, so the doses from those trials do not transfer to it cleanly, and there is no comparable body of human data establishing what an equivalent dose of the acetyl-amidate form even is. Borrowing a stroke regimen and applying it to a different peptide is an assumption, not a finding.

Community intranasal dosing — and why it is unvalidated

Outside the clinic, the doses people actually use for “cognition” or “focus” are far smaller than the stroke courses and are typically described as a few intranasal drops once or twice a day, often as a short on-off cycle. It is important to be blunt about what these numbers are: they are community conventions, not validated doses. No controlled trial has tested those amounts, on that schedule, for cognitive enhancement in healthy people. The closest well-controlled human data — a placebo-controlled imaging study — measured changes in resting-state brain networks rather than any clinical or cognitive outcome, and was not a dose-finding study.^[7]So the popular dosing folklore sits on top of an evidence base that was built for a different indication, a different population, and in the case of the acetyl-amidate product, a different molecule.

Safety and the case for supervision

Because Semax has never been through Western trials or post-marketing surveillance, the robust human safety data — the kind that defines dose ceilings, drug interactions and at-risk groups — is essentially absent from the published record outside Russia.^[6] The peptide’s parent molecule is an ACTH(4–10) fragment, which is reassuring in that the analog was deliberately stripped of hormonal activity, but the absence of evidence of harm is not evidence of its absence at the doses or durations people self-administer. The reasonable posture is that Semax is a real drug with a real but narrow evidence base, and that any decision to use it — route, dose, and duration — belongs with a clinician who can account for the missing safety picture, not with a vendor listing or a community thread.

The honest bottom line

Reduced to what can be defended: Semax is dosed intranasally, the Russian clinical studies used fixed daily therapeutic courses in stroke that are higher than typical nootropic use, and the registered Russian label is the only document with any official standing — one that does not apply in the US.^[3][4][5] The product most people buy is a modified acetyl-amidate form whose dosing has no comparable human data, and the small “microdoses” used for cognition are unvalidated conventions, not tested doses.^[6] Treat any number here as a description of practice, not a recommendation. Its anxiolytic sibling peptide, Selank, sits in the same evidentiary position.